Creating therapeutic cancer vaccines: notes from the battlefield.

With the identification of tumor antigens and a knowledge of how to vaccinate against them, the field of tumor immunology faces new challenges. In this article, the authors argue that successful immunotherapies of the future will activate anti-tumor T cells without inducing their anergy or apoptotic death.

[1]  N. Restifo.  The new vaccines: building viruses that elicit antitumor immunity. , 1996, Current opinion in immunology.

[2]  R. Schwartz,et al.  T-cell clonal anergy. , 1997, Cold Spring Harbor symposia on quantitative biology.

[3]  S. Sakaguchi.  Regulatory T cells , 2006, Springer Seminars in Immunopathology.

[4]  C. Lowenstein,et al.  The Central Role of CD4+ T Cells in the Antitumor Immune Response , 1998, The Journal of experimental medicine.

[5]  Dirk Schadendorf,et al.  Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells , 1998, Nature Medicine.

[6]  L. Zheng,et al.  T cell growth cytokines cause the superinduction of molecules mediating antigen-induced T lymphocyte death. , 1998, Journal of immunology.

[7]  F. Oesch,et al.  Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic‐T‐cell responses: Evidence for immunoselection of antigen‐loss variants in vivo , 1996, International journal of cancer.

[8]  S. Rosenberg,et al.  A new era for cancer immunotherapy based on the genes that encode cancer antigens. , 1999, Immunity.

[9]  R. Germain,et al.  Selective Induction of Apoptosis in Mature T Lymphocytes by Variant T Cell Receptor Ligands , 1998, The Journal of experimental medicine.

[10]  C. Melief,et al.  Specific T Helper Cell Requirement for Optimal Induction of Cytotoxic T Lymphocytes against Major Histocompatibility Complex Class II Negative Tumors , 1998, The Journal of experimental medicine.

[11]  J. Tschopp,et al.  Melanoma Cell Expression of Fas(Apo-1/CD95) Ligand: Implications for Tumor Immune Escape , 1996, Science.

[12]  S. Rosenberg,et al.  Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen. , 1995, Journal of immunology.

[13]  R. Zinkernagel,et al.  Induction and Exhaustion of Lymphocytic Choriomeningitis Virus–specific Cytotoxic T Lymphocytes Visualized Using Soluble Tetrameric Major Histocompatibility Complex Class I–Peptide Complexes , 1998, The Journal of experimental medicine.

[14]  E. Shevach.  Regulatory T cells in autoimmmunity*. , 2000, Annual review of immunology.

[15]  S. Rosenberg,et al.  Recognition of shared melanoma antigens in association with major HLA-A alleles by tumor infiltrating T lymphocytes from 123 patients with melanoma. , 2000, Journal of immunotherapy.

[16]  P. Doherty,et al.  Contemporary Analysis of MHC-Related Immunodominance Hierarchies in the CD8+ T Cell Response to Influenza A Viruses1 , 2000, The Journal of Immunology.

[17]  F. Marincola,et al.  Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma , 1998, Nature Medicine.

[18]  B. Moss,et al.  gp100/pmel 17 Is a Murine Tumor Rejection Antigen: Induction of “Self”-reactive, Tumoricidal T Cells Using High-affinity, Altered Peptide Ligand , 1998, The Journal of experimental medicine.

[19]  F. Marincola,et al.  Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. , 1998, Journal of the National Cancer Institute.

[20]  L. Old,et al.  Cancer Tumor antigens. , 1997, Current opinion in immunology.

[21]  N. Restifo,et al.  Cutting Edge: CD4+ T Cell Control of CD8+ T Cell Reactivity to a Model Tumor Antigen , 2000, The Journal of Immunology.

[22]  S. Rosenberg,et al.  Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy. , 1996, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

[23]  B. Moss,et al.  Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[24]  F. Marincola,et al.  Phase 1 Study in Patients With Metastatic Melanoma of Immunization With Dendritic Cells Presenting Epitopes Derived From the Melanoma-Associated Antigens MART-1 and gp100 , 2000, Journal of immunotherapy.

[25]  J. Kirkwood,et al.  Vitiligo in patients with metastatic melanoma: a good prognostic sign. , 1983, Journal of the American Academy of Dermatology.

[26]  S. Steinberg,et al.  Immune selection after antigen-specific immunotherapy of melanoma. , 1999, Surgery.

[27]  N. Restifo.  Not so Fas: Re-evaluating the mechanisms of immune privilege and tumor escape , 2000, Nature Medicine.

[28]  P. Musiani,et al.  A "stealth effect": adenocarcinoma cells engineered to express TRAIL elude tumor-specific and allogeneic T cell reactions. , 1999, Journal of immunology.

[29]  R. Germain,et al.  Variant TCR ligands: new insights into the molecular basis of antigen-dependent signal transduction and T-cell activation. , 1996, Seminars in immunology.

[30]  M. Jackson,et al.  TCR-Mediated internalization of peptide-MHC complexes acquired by T cells. , 1999, Science.

[31]  P. Klenerman,et al.  Immune surveillance against a solid tumor fails because of immunological ignorance. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[32]  A. Gross,et al.  Regression of human metastatic renal cell carcinoma after vaccination with tumor cell–dendritic cell hybrids , 2000, Nature Medicine.

[33]  D. Hanahan,et al.  Self Antigens Expressed by Solid Tumors Do Not Efficiently Stimulate Naive or Activated T Cells: Implications for Immunotherapy , 1997, The Journal of experimental medicine.